fda compounding glp-1 warning letters october 2025 Pharmacovigilance Assessment of Compounded GLP-1 Receptor Agonists: Insights From the FDA Adverse Event Reporting System FDA alerts health care providers,

Key points Key messages from the paper Incretin analogues (semaglutide, tirzepatide) provide effective glucose control in type 2 diabetes mellitus (T2DM) and major weight losses in people without diabetes

Read more about this update here: #OpioidSafety #PatientCare #FDAUpdate #HealthcareProfessionals To view or add a comment, sign in Medicare Part D Enrollment is here

Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin

Avoid snacks that deliver mostly carbohydrates or fat without meaningful protein

All together, current knowledge suggests that physical activity interventions in women with GDM should be encouraged unless obstetrical contraindications exist as physical activity may be an important component of GDM management